NOVELSTEM Share Price OTC Markets

NSTM

US4362331005

Biotechnology & Medical Research

Delayed OTC Markets 08:29:07 05/10/2021 pm IST			5-day change	1st Jan Change
0.2700 ^USD	+7.57%		-3.50%	+44.75%

14/08	NovelStem International Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
15/05	NovelStem International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

NovelStem International Corp. is a development stage biotechnology holding company focused on stem cell-based technology. The Company's primary assets are NewStem Ltd (NewStem) and NetCo Partners (NetCo). NewStem focuses on the development and commercialization of diagnostic technology that can predict patientsâ€™ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is principally focused on utilizing proprietary human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs) in the development of diagnostic and therapeutic products in oncology. Its NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. NetCo is a media business interest which owns Net Force, a book publishing franchise.

Employees

Sector

Biotechnology & Medical Research

More about the company

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!

SEIZE THE OFFER!

Market Cap	5L 4L 4L 3L 6L 4.44Cr 6L 44.92L 17.38L 2.27Cr 17.6L 17.21L 7.23Cr	P/E 2024	-0.11x	P/E 2025	0.18x
Enterprise Value	23.72L 20.4L 19.19L 17.51L 32.68L 22Cr 32.85L 2.27Cr 87.96L 11Cr 89.08L 87.13L 37Cr	EV / Sales 2024	39,81,32,333x	EV / Sales 2025	-
Free-Float	38.73%	Yield 2024 *	-	Yield 2025	-

14/08	NovelStem International Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
15/05	NovelStem International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
26/03	NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
26/03	NovelStem International Corp. Auditor Raises 'Going Concern' Doubt	CI
13/11	NovelStem International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
07/25/07	NovelStem International Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
20/25/20	NovelStem International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
08/25/08	NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
07/25/07	NovelStem International Corp. Auditor Raises 'Going Concern' Doubt	CI
15/24/15	NovelStem International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
15/24/15	NovelStem International Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
16/24/16	NovelStem International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02/24/02	NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

20/25/20	NovelStem Announces Material Developments and Strategic Repositioning of the Company	AQ
01/23/01	NOVELSTEM INTERNATIONAL CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
18/23/18	NOVELSTEM INTERNATIONAL CORP. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
15/22/15	NOVELSTEM INTERNATIONAL CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
04/22/04	NOVELSTEM INTERNATIONAL CORP. : Change in Directors or Principal Officers (form 8-K)	AQ

Manager	Title	Age	Since
Christine Jenkins DFI	Director of Finance/CFO	63	29/09/2022
Jan Loeb PSD	President	67	13/01/2023

Director	Title	Age	Since
Mitchell Rubenstein CHM	Chairman	72	22/01/1993
Jan Loeb CHM	Chairman	67	01/07/2018
Eric Richman BRD	Director/Board Member	65	01/06/2018

NOVELSTEM Share Price OTC Markets

Stocks

NSTM

US4362331005

Biotechnology & Medical Research

Valuation : NOVELSTEM

Latest news : NOVELSTEM

Press Releases : NOVELSTEM

Quotes and Performance

Managers and Directors : NOVELSTEM

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NOVELSTEM	+7.57%	-3.50%	-	-	5L
WUXI APPTEC CO., LTD.	+2.02%	+1.26%	+41.37%	+105.18%	6.92TCr
ARGENX SE	-1.02%	-4.75%	+31.40%	+74.46%	6.3TCr
INSMED INCORPORATED	-1.11%	+2.78%	-14.86%	+375.59%	2.73TCr
BIONTECH SE	-4.92%	-3.22%	-3.90%	-17.87%	2.48TCr
WUXI BIOLOGICS (CAYMAN) INC.	-1.14%	-1.14%	+29.26%	+14.00%	2.58TCr
GENMAB A/S	+0.28%	-0.18%	+23.42%	-16.24%	2.01TCr
PHARMAESSENTIA CORPORATION	+6.04%	+7.25%	+233.25%	+383.12%	1.85TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.48%	-2.47%	-8.16%	+515.62%	1.49TCr
EXELIXIS, INC.	-2.27%	+1.37%	+53.01%	+160.83%	1.43TCr
Average	+0.39%	+0.74%	+42.76%	+177.19%	3.09TCr
Weighted average by Cap.	-0.14%	+0.11%	+37.83%	+139.85%

	2024	2025
Net sales	0.01 0.01 0.01 0.01 0.02 1.14 0.02 0.12 0.04 0.58 0.05 0.04 1.85	-
Net income	-32.33L -27.8L -26.15L -23.87L -44.54L -31Cr -44.77L -3.1Cr -1.2Cr -16Cr -1.21Cr -1.19Cr -50Cr	23.8L 20.46L 19.25L 17.57L 32.78L 23Cr 32.95L 2.28Cr 88.25L 12Cr 89.37L 87.42L 37Cr
Net Debt	44.12L 37.93L 35.69L 32.57L 60.78L 42Cr 61.09L 4.23Cr 1.64Cr 21Cr 1.66Cr 1.62Cr 68Cr	19.03L 16.37L 15.4L 14.05L 26.22L 18Cr 26.36L 1.82Cr 70.58L 9.22Cr 71.48L 69.92L 29Cr